Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.12
CPHD's Cash to Debt is ranked lower than
61% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. CPHD: 1.12 )
Ranked among companies with meaningful Cash to Debt only.
CPHD' s Cash to Debt Range Over the Past 10 Years
Min: 0.99  Med: 12.93 Max: 11006.5
Current: 1.12
0.99
11006.5
Equity to Asset 0.45
CPHD's Equity to Asset is ranked lower than
71% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CPHD: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
CPHD' s Equity to Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.73 Max: 0.92
Current: 0.45
0.45
0.92
F-Score: 5
Z-Score: 3.30
M-Score: -3.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -5.73
CPHD's Operating margin (%) is ranked lower than
54% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. CPHD: -5.73 )
Ranked among companies with meaningful Operating margin (%) only.
CPHD' s Operating margin (%) Range Over the Past 10 Years
Min: -34.65  Med: -10.40 Max: 1.37
Current: -5.73
-34.65
1.37
Net-margin (%) -9.01
CPHD's Net-margin (%) is ranked lower than
55% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. CPHD: -9.01 )
Ranked among companies with meaningful Net-margin (%) only.
CPHD' s Net-margin (%) Range Over the Past 10 Years
Min: -29.75  Med: -11.74 Max: 0.95
Current: -9.01
-29.75
0.95
ROE (%) -13.17
CPHD's ROE (%) is ranked lower than
56% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. CPHD: -13.17 )
Ranked among companies with meaningful ROE (%) only.
CPHD' s ROE (%) Range Over the Past 10 Years
Min: -27.63  Med: -16.09 Max: 1.44
Current: -13.17
-27.63
1.44
ROA (%) -5.96
CPHD's ROA (%) is ranked lower than
52% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. CPHD: -5.96 )
Ranked among companies with meaningful ROA (%) only.
CPHD' s ROA (%) Range Over the Past 10 Years
Min: -19.19  Med: -10.06 Max: 1.04
Current: -5.96
-19.19
1.04
ROC (Joel Greenblatt) (%) -14.87
CPHD's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. CPHD: -14.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPHD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -189.08  Med: -37.31 Max: 5.58
Current: -14.87
-189.08
5.58
Revenue Growth (3Y)(%) 17.30
CPHD's Revenue Growth (3Y)(%) is ranked higher than
82% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. CPHD: 17.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPHD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.4  Med: 18.70 Max: 56.7
Current: 17.3
-15.4
56.7
» CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CPHD Guru Trades in Q1 2015

Jim Simons 51,950 sh (New)
PRIMECAP Management 2,323,600 sh (+0.58%)
Mario Gabelli 233,500 sh (unchged)
Ron Baron 860,003 sh (-2.79%)
Columbia Wanger 6,492,300 sh (-9.87%)
» More
Q2 2015

CPHD Guru Trades in Q2 2015

RS Investment Management 310,520 sh (New)
Jim Simons 295,250 sh (+468.33%)
PRIMECAP Management 2,335,100 sh (+0.49%)
Ron Baron 846,834 sh (-1.53%)
Mario Gabelli 214,500 sh (-8.14%)
Columbia Wanger 5,582,372 sh (-14.02%)
» More
Q3 2015

CPHD Guru Trades in Q3 2015

Steven Cohen 175,000 sh (New)
RS Investment Management 414,860 sh (+33.60%)
PRIMECAP Management 2,363,400 sh (+1.21%)
Ron Baron 856,093 sh (+1.09%)
Mario Gabelli 214,500 sh (unchged)
Jim Simons Sold Out
Columbia Wanger 5,095,274 sh (-8.73%)
» More
Q4 2015

CPHD Guru Trades in Q4 2015

Mario Gabelli 231,500 sh (+7.93%)
Columbia Wanger 5,360,677 sh (+5.21%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 40.82
CPHD's Forward P/E is ranked lower than
86% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.32 vs. CPHD: 40.82 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.70
CPHD's P/B is ranked lower than
74% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. CPHD: 5.70 )
Ranked among companies with meaningful P/B only.
CPHD' s P/B Range Over the Past 10 Years
Min: 2.25  Med: 8.57 Max: 14.01
Current: 5.7
2.25
14.01
P/S 4.01
CPHD's P/S is ranked lower than
56% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. CPHD: 4.01 )
Ranked among companies with meaningful P/S only.
CPHD' s P/S Range Over the Past 10 Years
Min: 1.76  Med: 6.63 Max: 13.39
Current: 4.01
1.76
13.39
POCF 88.35
CPHD's POCF is ranked lower than
93% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.31 vs. CPHD: 88.35 )
Ranked among companies with meaningful POCF only.
CPHD' s POCF Range Over the Past 10 Years
Min: 45.32  Med: 137.62 Max: 1642.33
Current: 88.35
45.32
1642.33
Current Ratio 3.88
CPHD's Current Ratio is ranked higher than
64% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. CPHD: 3.88 )
Ranked among companies with meaningful Current Ratio only.
CPHD' s Current Ratio Range Over the Past 10 Years
Min: 1.49  Med: 3.13 Max: 15.23
Current: 3.88
1.49
15.23
Quick Ratio 2.88
CPHD's Quick Ratio is ranked higher than
58% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. CPHD: 2.88 )
Ranked among companies with meaningful Quick Ratio only.
CPHD' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.35 Max: 14.9
Current: 2.88
0.89
14.9
Days Inventory 191.77
CPHD's Days Inventory is ranked lower than
85% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. CPHD: 191.77 )
Ranked among companies with meaningful Days Inventory only.
CPHD' s Days Inventory Range Over the Past 10 Years
Min: 57.37  Med: 133.93 Max: 188.21
Current: 191.77
57.37
188.21
Days Sales Outstanding 45.10
CPHD's Days Sales Outstanding is ranked higher than
77% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. CPHD: 45.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.78  Med: 48.86 Max: 63.71
Current: 45.1
40.78
63.71
Days Payable 78.14
CPHD's Days Payable is ranked higher than
68% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. CPHD: 78.14 )
Ranked among companies with meaningful Days Payable only.
CPHD' s Days Payable Range Over the Past 10 Years
Min: 39.64  Med: 78.22 Max: 95.58
Current: 78.14
39.64
95.58

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.10
CPHD's Price/Net Current Asset Value is ranked lower than
83% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. CPHD: 20.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPHD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.35  Med: 16.76 Max: 50.57
Current: 20.1
2.35
50.57
Price/Tangible Book 6.91
CPHD's Price/Tangible Book is ranked lower than
63% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. CPHD: 6.91 )
Ranked among companies with meaningful Price/Tangible Book only.
CPHD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.1  Med: 10.72 Max: 20.53
Current: 6.91
2.1
20.53
Price/Projected FCF 21.28
CPHD's Price/Projected FCF is ranked lower than
97% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. CPHD: 21.28 )
Ranked among companies with meaningful Price/Projected FCF only.
CPHD' s Price/Projected FCF Range Over the Past 10 Years
Min: 17.83  Med: 32.99 Max: 94.71
Current: 21.28
17.83
94.71
Price/Median PS Value 0.61
CPHD's Price/Median PS Value is ranked higher than
76% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. CPHD: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
CPHD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 1.17 Max: 4.27
Current: 0.61
0.37
4.27
Earnings Yield (Greenblatt) (%) -2.28
CPHD's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CPHD: -2.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPHD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.28  Med: 0.20 Max: 0.3
Current: -2.28
-2.28
0.3

More Statistics

Revenue(Mil) $539
EPS $ -0.68
Beta0.21
Short Percentage of Float10.04%
52-Week Range $26.22 - 63.69
Shares Outstanding(Mil)72.34

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 604 708
EPS($) -0.32 0.68
EPS without NRI($) -0.32 0.68

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:XEP.Germany,
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
» More Articles for NAS:CPHD

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Cepheid Feb 08 2016 
Columbia Wanger Ups Stake in Fiesta Restaurant Feb 01 2016 
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Cepheid Incurs Loss in Q4 as Margins Drop; Revenues Up Y/Y Feb 04 2016
Cepheid Earnings Analysis: 2015 By the Numbers Feb 04 2016
Cepheid to Webcast Upcoming Financial Presentations Feb 03 2016
Edited Transcript of CPHD earnings conference call or presentation 2-Feb-16 10:00pm GMT Feb 02 2016
Cepheid reports 4Q loss Feb 02 2016
Cepheid reports 4Q loss Feb 02 2016
CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and... Feb 02 2016
Cepheid Reports Fourth Quarter And Full Year 2015 Results Feb 02 2016
Q4 2015 Cepheid Earnings Release - After Market Close Feb 02 2016
Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials... Jan 13 2016
Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials... Jan 13 2016
Cepheid – Value Analysis (NASDAQ:CPHD) : January 12, 2016 Jan 12 2016
Cepheid Schedules 2015 Fourth Quarter And Full Year Results Announcement And Webcast Jan 11 2016
CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and... Jan 11 2016
Cepheid breached its 50 day moving average in a Bearish Manner : January 11, 2016 Jan 11 2016
Cepheid Schedules 2015 Fourth Quarter And Full Year Results Announcement And Webcast Jan 11 2016
Take Profits Judiciously When You're Short A Stock Jan 08 2016
USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug-Resistant... Jan 07 2016
USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug-Resistant... Jan 07 2016
Cepheid's GeneXpert System to be Distributed by Henry Schein Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK